The Bottom Line
Tranexamic acid (TXA) is emerging as one of the most effective treatments for melasma and hyperpigmentation, available in both oral (250mg twice daily) and topical (2-5%) forms. Originally a blood-clotting medication, it reduces melanin production by blocking the interaction between keratinocytes and melanocytes. Multiple studies show significant improvement in melasma — sometimes comparable to hydroquinone but with fewer side effects.
How Tranexamic Acid Works for Skin
TXA is a synthetic amino acid that inhibits plasminogen activator, which reduces the production of prostaglandins and arachidonic acid — both of which stimulate melanocytes. The net effect: melanocytes produce less melanin, and existing pigmentation gradually fades.
Unlike hydroquinone (which directly inhibits the tyrosinase enzyme), TXA works upstream — it reduces the signals that tell melanocytes to produce pigment in the first place. This different mechanism means it can work when hydroquinone doesn't, and the two can be combined for enhanced results.
Evidence for Melasma
- A 2020 systematic review in JAAD analyzing 23 studies found that oral TXA significantly improved melasma severity scores in the majority of patients
- One randomized controlled trial showed oral TXA (250mg twice daily for 3 months) was as effective as triple combination cream (hydroquinone + tretinoin + steroid) with fewer side effects
- Topical TXA (3-5%) showed significant improvement in melasma severity index (MASI) scores after 12 weeks in multiple studies
- Intradermal injection of TXA has also shown benefit in small studies
Oral vs. Topical TXA
Oral TXA (250mg twice daily):
- More studied, potentially more effective for widespread melasma
- Systemic — addresses pigmentation from inside out
- Risk: potential blood clotting effects (contraindicated in women with clotting history, on estrogen-containing birth control, or with cardiovascular risk factors)
- Requires medical supervision and monitoring
Topical TXA (2-5% serum or cream):
- Minimal systemic absorption — much safer from a clotting perspective
- Can be used long-term as maintenance
- Available OTC in many skincare products
- May be less potent than oral for severe melasma
- Best applied twice daily, can be layered with other actives (vitamin C, niacinamide)
How to Use Topical TXA
- Apply to clean, dry skin before heavier products
- Use twice daily (morning and evening) for best results
- Compatible with most other skincare ingredients (vitamin C, retinoids, niacinamide, AHAs)
- Always pair with broad-spectrum SPF 30+ — UV exposure will undo TXA's benefits
- Allow 8-12 weeks for visible improvement
Frequently Asked Questions
Is oral tranexamic acid safe?
For most healthy women without clotting risk factors, yes — at the low doses used for melasma (250mg twice daily). The doses used for melasma are much lower than those used for heavy menstrual bleeding (typically 1,000-1,300mg three times daily). However, it's contraindicated in women with history of blood clots, those on estrogen-containing contraceptives, smokers over 35, and those with certain cardiovascular conditions.
How does TXA compare to hydroquinone?
Both are effective for melasma, working through different mechanisms. Hydroquinone directly inhibits melanin production; TXA reduces the upstream signals. TXA has fewer side effects (no ochronosis risk, no irritation) and can be used longer-term. Many dermatologists now use TXA as a maintenance treatment after initial clearing with hydroquinone.
Can I use TXA during pregnancy?
Topical TXA has minimal systemic absorption and is generally considered low-risk, though formal pregnancy safety studies are lacking. Oral TXA is Category B but should be discussed with your OB-GYN. Many dermatologists prefer to wait until postpartum for both forms.
- Rodrigues M, et al. "Treatment of melasma with oral tranexamic acid: a systematic review." JAAD. 2020;83(6):1554-1563.
- Del Rosario E, et al. "Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma." JAAD. 2018;78(2):363-369.
- Taraz M, et al. "Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies." Dermatologic Therapy. 2017;30(3):e12465.